Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let’s go, boys. Pump this fkr and let me out.
$AWH- Loads of insider Buying
Private investor buys 38% of the company shares
Up 5.4% Pre-Market/ Current Price $2.58
CEO Nichole picks up 12,000 shares at $3.98 a lot of insider buys with this financing Very Bullish
$AWH - Up 6% Pre-Market/ Current Price $2.68
Entered into a securities purchase agreement for 1,694,820 shares for $4.7 million
Insider buys for about 14,000 shares
Ready to Run Lets Go!
Love the chart as we bottomed, consolidated and now accumulation is underway along with a possible short squeeze.
3 great presentations by the CEO at various investor events over the last month. Partnership with ABBV for Endometriosis testing ($1.2B-$4B market) along with OVA1 tests back at pre-Covid levels, more insurers coming on board like Anthem who controls 21 BC/BS throughout the US.
Making great strides on replacing CA-125 with OVA1 as the SOC which would result in $1B in annual sales.
By 2023 you could be looking at a multi-billion annual revenue stream for AWH.
10 million shares short and float is very small as most shares tied up with insiders and other investors who aren't selling. Going to be a fun run into year end and then the smoke show begins in 2021.
New 52 week highs coming around the corner.
Yea that's what caused the big pop in price and volume surge. Unfortunately, we didn't hold the gains this week and we will see what comes of an actual deal?
MYOV spoke about AWH?
Deal with MYOV and ABBV forthcoming for Endometriosis. MYOV spoke about it today on a call with their new drug. We also know CEO of AWH has stated they are in talks with ABBV for the same test. Might explain the volume and price action today? Good time to buy in before this one moon shots. JMO
SO GLAD I SOLD BEFORE FILINGS.. HAD A FEELING AWH
The new week... will be fondamental
Very excited about the upcoming week and earnings conference call.
We are finally the SOC for Ovarian Cancer Testing and growth has now take off with numbers exceeding 50% quarter over quarter. If Covid-19 didn't hit this stock would already be at $10 a share as testing slowed down, but is starting to regain momentum. 2nd half will be phenomenal.
We will hear about new branding and overall company strategy and a lot more like the following updates:
We could/should hear about new insurance coverage which is key as we added Cigna and Medicare in the 1st quarter opening us up to 160 million possible patients. More insurers to follow.
We could/should hear about new networks of clinics with vast #'s of physicians now using OVA1 for all their Ovarian cancer testing.
We could/should get an update on other partnerships along with Endometriosis progess with possible BP partner.
The sky is the limit and so is the stock price.
AWH have several key catalysts that will drive this stock to new 52 week highs and they should be all around upcoming earnings call in early-mid August.
1.) Announcement of a major doctor network (up to 3500) that will be utilizing OVA1 in their practices and as the SOC for testing Ovarian cancer.
2.) Announcement of a partnership with a major player (possibly Abbvie) for endometriosis test and other collaborations.
3,) Earnings call with forward guidance showing substantial growth.
Big accumulation of stock over last several months and now a nice consolidation pattern in that $3.75-$4.50 range. We should break out shortly (next two weeks) and obviously any of the above news events will be a catalyst to take us to new highs.
This company will be bought out by Quest Diagnostics, Roche or some other large entity in the healthcare space now that insurance is in place.
I'm waiting to see a new 13D or G filing...
https://fintel.io/so/us/vrml
Loving this AWH the last few days, MWM.......!
Very solid trading, indeed !
$$ AWH $$
10 dollar and if at august ..good news ...20
We start trading tomorrow with the new ticker.... in Europe
We hope for 7
VRML everyone came late, I was screaming since 2.50!
$VRML $AWH so did all the insiders buy the warrants? If they did then that is a STRONG showing of Confidence! WOW!
$VRML closing well! Looking forward to the Name change and new symbol tomorrow!
$AWH
That would be awesome!
I agree, I added some $5 calls for June as well. At .20 cents these are cheap! I think this catches a major bid once the name and symbol change takes place on June 12th. I believe todays prices are a gift. Good Luck to all of us here!
I think it could easily bounce right back up. Fingers crossed!
Maybe tomorrow, with the new symbol ........ we can hope !!
I agree, DT !! Nice grab on your options !!
I got a few more June 19th, $5.00 calls today for cheap......we’re looking really good here, imho......the crazy overall market is giving us a nice loading opportunity.......lol.
I'll take some more news of massive OVA1 adoption!
Yes!!! They will have to cover! This is going to be a lot of fun soon!!
Looking forward to our symbol change and the required covering of all outstanding short shares in the process......!
$$ VRML $$
Damn, yes you did!
I Bought some January $5 calls for $1.05! I stole those!
TIME TO BUY
Load all.you can
Clearly they are in the middle of a PR/Rebranding blitz. I'm going to stick around that is for sure!
These folks are certainly not stagnant.......we never know what new direction we’re heading !
Still have most of my June 19th $5.00 calls.......let’s see what today brings......lol.
Vermillion, Inc. Announces Rebranding and Company Name Change to Aspira Women’s Health Inc.
June 11, 2020 08:31 ET
AUSTIN, Texas, June 11, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on ovarian cancer risk assessment, today announced a major rebranding to reflect the company’s continuing evolution towards becoming a comprehensive gynecologic health company, including a corporate name change to Aspira Women’s Health Inc effective today, June 11, 2020. The company’s common stock will trade on the Nasdaq Stock Market under the new ticker symbol “AWH” effective June 12, 2020.
Over the past 12 months, Aspira Women’s Health has established its foundation as the market leader for ovarian cancer risk assessment while beginning product development to expand into large benign gynecologic disease markets. The company’s goal is to serve the large pelvic mass market, 20 million women in the US, and 200 million women worldwide, with proprietary products throughout the entire patient lifecycle. The Company has experienced an increase in its US customer base of ordering physicians from 1,400 in 2018 to 2,700 for 2019, a 56% increase. The Company has 85 filed and 40 pending patents. This growth reflects the trust and adoption of OVA1 ® plus coupled with real-time innovations such as the addition of germline genetic testing and ethnic disparity solutions. Portfolio expansion development includes: pelvic mass monitoring, endometriosis, and high-risk ovarian cancer screening for those genetically predisposed.
“Today marks a significant milestone for our company,” said Valerie Palmieri, President, and Chief Executive Officer of Aspira Women’s Health. “Our new company name captures the soul of our company’s mission and vision. With this name change, we are solidifying our commitment to solving big women’s health issues such as endometriosis and ovarian cancer detection for all ethnicities, stages, and ages. Through our data-driven approach, we aim to deliver solutions that help women “Aspire” to take control of their gynecologic health and “Empower” providers to deliver optimal care.”
As part of the name change, the company has a new stock ticker symbol (AWH) and a new CUSIP (04537Y109) and has relaunched its website as www.aspirawh.com , and rolled out a new company logo and associated icon pictorially connecting the dots for gynecologic women’s health.
The company has used the name, “Vermillion Inc.” for more than 13 years, during which it has been known for developing FDA cleared ovarian cancer risk assessment tests OVA1 ® and OVERA ® . The name change will not affect the quality of products or services offered by the company.
The Company anticipates holding a conference call later this month to discuss the rebranding and expanded portfolio. Details of the call will follow on a later date.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. (formerly known as Vermillion, Inc. Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 ® plus combines our FDA-cleared products OVA1 ® and OVERA ® to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiX SM testing offers both targeted and a more comprehensive genetic testing options with a gynecologic focus. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment. Visit our website for more information about our products at www.aspirawh.com .
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-430-7577
Arr@lifesciadvisors.com
Me too.......,lol.
That was a HARD shake......!!
You must have taken your Nexium to hold thru that, Mike, but all looks much better now.
I’ve got my June 19th......$5.00 calls, and I’m holding them all dang it.....lol.